1. Home
  2. ACRS vs BYND Comparison

ACRS vs BYND Comparison

Compare ACRS & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$4.59

Market Cap

311.0M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$0.82

Market Cap

269.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
BYND
Founded
2012
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
311.0M
269.7M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
ACRS
BYND
Price
$4.59
$0.82
Analyst Decision
Strong Buy
Sell
Analyst Count
5
7
Target Price
$10.20
$0.83
AVG Volume (30 Days)
1.1M
49.4M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
24.69
EPS
N/A
N/A
Revenue
$1,683,000.00
$275,496,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.24
$1.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.34
$0.50
52 Week High
$5.15
$7.69

Technical Indicators

Market Signals
Indicator
ACRS
BYND
Relative Strength Index (RSI) 53.24 51.36
Support Level $4.15 $0.81
Resistance Level $4.89 $1.09
Average True Range (ATR) 0.22 0.05
MACD -0.05 -0.01
Stochastic Oscillator 37.50 58.92

Price Performance

Historical Comparison
ACRS
BYND

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: